G. Prat et al., The novel type B MAO inhibitor PF9601N enhances the duration of L-DOPA-induced contralateral turning in 6-hydroxydopamine lesioned rats, J NEURAL TR, 107(4), 2000, pp. 409-417
The present study examined the effect of the highly potent and selective MA
O B inhibitor PF9601N on L-DOPA-induced rotational behavior in unilateral n
igrostriatal 6-hydroxydopamine lesioned rats. Three doses of PF9601N (20, 4
0 and 60 mg/kg) were administered 30 min before an injection of L-DOPA (25
mg/kg), and both contralateral and ipsilateral rotational behavior was meas
ured. In addition, we also studied the effect produced by another MAO B inh
ibitor, deprenyl (20 mg/kg), the MAO A inhibitor, clorgyline (20 mg/kg), an
d the dopamine reuptake inhibitor, GBR2909 (7.5 mg/kg) on L-DOPA-induced ro
tational behavior. The results showed that PF9601N plus L-DOPA significantl
y enhanced the duration of contralateral rotational behavior with respect t
o L-DOPA plus vehicle in a dose-related manner. At the dose of 30 and 60 mg
/kg, PF9601N produced significantly more overall contralateral turning than
L-DOPA plus vehicle, and at the dose of 60 mg/kg, PF9601N produced signifi
cantly more turning behavior than L-DOPA plus deprenyl. These results sugge
st that PF9601N may be used as a novel tool in the treatment of Parkinson's
disease.